Belite Bio
BLTE | NASDAQ
$162.56
-$1.79 (-1.09%)
At close: Nov 16, 2026, 4:00 PM ET
$163.00
+$0.44 (+0.27%)
After-hours:
Nov 16, 2026, 4:30 PM ET
Belite Bio Company Profile
Company profile explainedCompany Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Key Executives
| Name | Position |
|---|---|
| Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer |
| Hao-Yuan Chuang | Chief Financial Officer & Director |
| Hendrik Scholl | Chief Medical Officer |
| Kelly Kilpatrick | Chief Commercial Officer |
| Nathan L. Mata | Chief Scientific Officer |
Belite Bio
| Country | United States |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Yu-Hsin Lin |
Contact Details
12750 High Bluff Drive San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | BLTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001889109 |
| CUSIP Number | 07782B104 |
| ISIN Number | US07782B1044 |
| SIC Code | 2834 |
Recent News
- 4 days ago / marketbeat.comWhat Belite Bio (BLTE) Said on Its Q3 Earnings Call
- 4 days ago / seekingalpha.comBelite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
- 4 days ago / globenewswire.comBelite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
- 12 days ago / globenewswire.comBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
- 1 month ago / globenewswire.comBelite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
- 2 months ago / globenewswire.comBelite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- 2 months ago / seekingalpha.comBelite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / zacks.comBelite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
- 2 months ago / globenewswire.comBelite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
- 2 months ago / benzinga.comWhy Is Belite Bio Stock Soaring Friday?
Add to Watchlist
Select watchlists to add or remove BLTE